S-1: Alpha Cognition Files for Potential Offering of 42.7 Million Common Shares

Alpha Cognition Inc. has filed a registration statement for the potential offering and resale of up to 42,676,511 common shares by selling stockholders.

Summary

• Alpha Cognition Inc., a biopharmaceutical company, has filed a Form S-1 registration statement with the SEC.
• The filing covers the potential offering and resale of up to 42,676,511 common shares by existing selling stockholders.
• These shares were previously issued in private placements between August 2023 and January 2024.
• Alpha Cognition will not receive any proceeds from the sale of these shares.
• The company is focused on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease, with its lead candidate being ALPHA-1062.
• ALPHA-1062 is an oral tablet formulation under FDA review for mild-to-moderate Alzheimer's disease, with a PDUFA goal date of July 27th, 2024.
• The company is also pursuing other development programs, including ALPHA-1062 in combination with memantine for moderate-to-severe Alzheimer's, and an intranasal formulation for traumatic brain injury.
• Alpha Seven Therapeutics, in which Alpha Cognition retains a majority ownership, is focused on advancing the intranasal formulation of ALPHA-1062 for traumatic brain injury.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced reporting requirements.
• The company's common shares are traded on the CSE under the symbol ACOG and on the OTCQB under the symbol ACOGF.
• On April 19, 2024, the last reported sale price of the company's common shares on the CSE was C$0.66 and the last quoted price of the company's common shares on the OTCQB was $0.52.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the FDA review of ALPHA-1062 and the potential for out-licensing the TBI indication, there are also significant risks and uncertainties related to the company's financial condition and the regulatory approval process.

Positives

• The company has a Prescription Drug User Fee Act (PDUFA) goal date of July 27th, 2024 for ALPHA-1062.
• The company has a management team with experience in drug development and commercialization.
• The company has out-licensed its TBI indication to Alpha Seven, allowing for focused development and funding of that program.
• The company has filed a new composition-of-matter patent that secures broad protection for its lead asset, ALPHA-1062, currently under review by the FDA for mild-to-moderate Alzheimers Disease. If approved, the patent will secure composition-of-matter protection for an oral formulation of ALPHA-1062 into 2044, adding to other patent protection that currently protects ALPHA-1062 through 2042 in US and 2041 in other territories around the world.

Negatives

• The company will not receive any proceeds from the sale of common shares by the selling stockholders.
• The company has incurred significant net losses since inception and expects to continue to incur significant expenses and operating losses for the foreseeable future.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a limited operating history and no history of commercializing products.
• The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of ALPHA-1062.
• The company faces significant competition in an environment of rapid technological and scientific change.

Risks

• The company's ability to generate revenue and achieve profitability depends significantly on its ability to achieve several objectives relating to the FDA review of its filed NDA.
• The company may encounter substantial delays in its preclinical studies and clinical trials or may not be able to conduct or complete its preclinical studies or clinical trials on the timelines it expects, if at all.
• Use of the company's therapeutic candidates could be associated with side effects, adverse events, or other properties or safety risks.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• The company relies on third-party suppliers to manufacture its product candidates, and it intends to rely on third parties to produce commercial supplies of any approved product.
• The company is subject to certain supply chain risks inherent in manufacturing its lead product, ALPHA-1062, and future products with respect to Taiwan.
• The validity, scope, and enforceability of any patents listed in the Orange Book that cover the company's product candidates including its lead product candidate ALPHA-1062 can be challenged by third parties.
• The company may become involved in lawsuits to protect or enforce its patents or its other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.
• The company's stock price may be volatile, and you may not be able to resell common shares at or above the price you paid.
• Unfavorable global economic or political conditions could adversely affect the company's business, financial condition, or results of operations.

Future Outlook

The company plans to continue its development and commercialization activities for ALPHA-1062 in mild-to-moderate Alzheimers disease, including the commercial manufacturing for ALPHA-1062 and pursue the out-licensing of its TBI indication to Alpha Seven.

Management Comments

• The company's executive team comprises of pharmaceutical experts with over 27 drug approvals and 33 commercial launches, specifically in the Central Nervous System and the Alzheimers Disease space.
• The company believes ALPHA-1062 works in two different ways within the brain, by (1) raising the concentration of an essential chemical that transmits signals between nerve cells called acetylcholine, and (2) increasing the sensitivity of another chemical, called nicotinic acetylcholine receptors (nAChRs), which also enhances acetylcholine, regulates inflammation, defends against the loss of amyloid and strengthens other transmitters within the brain.

Industry Context

The document mentions that the Alzheimers disease market is characterized by strong and increasing competition, and a strong emphasis on intellectual property.

Comparison to Industry Standards

• Current generic competitors in the Alzheimers Disease market include donepezil, rivastigmine, galantamine, and memantine.
• Branded competitors include Namzaric by maker Abbvie and newly approved Adlarity by maker Corium.
• Alzheimers Disease companies developing therapeutics for similar indications include large companies with significant financial resources, such as Biogen, Eli Lilly, Corium, Taurz, Vasopharm.
• Neuren Pharmaceuticals, Abliva, and AB Science.
• In the Traumatic Brain Injury market, there are no current acute or chronic treatments approved to date.
• Companies currently in clinical trials for Traumatic Brain Injury include Vasopharm, SanBio/Sumitomo, Ostuka/Avanir Pharmaceuticals, Biogen, and Cellvation.

Related Party Transactions

• The company has outstanding warrants denominated in both Canadian and U.S. Dollars.
• The foreign exchange risk associated with the variable of the Canadian Dollar denominated warrant and the company's resulting U.S. Dollar denominated functional currency could result in a significant risk of loss at the date of valuing the risk and cause the company to incur a significant non-cash derivative liability depending on the exchange rate and share price volatility, share price, risk-free interest rate, and remaining life of the Canadian Dollar denominated warrants.

Stakeholder Impact

• The document outlines potential impacts on shareholders, patients, and caregivers, particularly regarding treatment options and commercial success of ALPHA-1062.

Next Steps

• The company will need to respond to regulatory questions and inquiries from FDA in a satisfactory manner and negotiate the commercial label and approval of the product with FDA, which is anticipated in Q3 2024.
• The company plans to continue its development activities and commercialization preparations around ALPHA-1062.
• The company plans to complete the out-license the TBI asset into Alpha Seven where Alpha Seven plans to raise the additional capital to advance the TBI program.

Key Dates

Keywords

ALPHA-1062, Alzheimer's disease, biopharmaceutical, clinical trials, FDA, NDA, regulatory approval, neurodegenerative diseases, pharmaceutical, private placement, common shares, warrants, emerging growth company, smaller reporting company, Alpha Seven Therapeutics, traumatic brain injury, TBI, mTBI, commercialization